F2G Ltd–Novo Group: investment, 202208 financing round totalling $70m inc existing + co-investor Novo Holdings |
2022-08-04 |
F2G Ltd–SEVERAL: investment, 202208 financing round $70m co-led by new investors Forbion + Sofinnova Partners |
2022-08-04 |
F2G Ltd–Sofinnova: investment, 202208 financing round totalling $70m inc new + co-lead investor Sofinnova Partners |
2022-08-04 |
Forty51 Ventures–Fischli Group: investment, 202207 first closing totalling $43m of Forty51 Ventures I fund incl co-lead investor Fischli Family |
2022-07-18 |
Forty51 Ventures–OTHER: investment, 202207 first closing totalling $43m of Forty51 Ventures I fund incl biotech entrepreneures + private individuals |
2022-07-18 |
Forty51 Ventures–SEVERAL: investment, 202207 first $43m closing of Forty51 Ventures I fund |
2022-07-18 |
Forty51 Ventures–Stable Asset Management: investment, 202207 first closing totalling $43m of Forty51 Ventures I fund incl co-lead investor SAM |
2022-07-18 |
Agomab Therapeutics–OTHER: investment, 202207 financing round Series B extension totalling $40.5m incl existing-investors |
2022-07-13 |
Agomab Therapeutics–SEVERAL: investment, 202207 financing round Series B extension $40.5m led by Pfizer bringing total Series B to $114m |
2022-07-13 |
Biosyntia–ECBF: investment, 202207 financing round Series B totalling €11.5m incl new + lead investor ECBF |
2022-07-07 |
Biosyntia–Novo Group: investment, 202207 financing round Series B totalling €11.5m incl existing + co-investor Novo Seeds |
2022-07-07 |
Biosyntia–SEVERAL: investment, 202207 financing round Series B €11.5m led by new investor ECBF |
2022-07-07 |
Biosyntia–Sofinnova: investment, 202207 financing round Series B totalling €11.5m incl existing + co-investor Sofinnova Partners |
2022-07-07 |
Ganymed Robotics–BNP Paribas: investment, 202207 financing round Series B first closing totalling €21m incl co-investor BNP Paribas Développement |
2022-07-07 |
Ganymed Robotics–Cathay Capital: investment, 202207 financing round Series B first closing totalling €21m incl lead investor Cathay Health |
2022-07-07 |
Ganymed Robotics–Crédit Mutuel-CIC: investment, 202207 financing round Series B first closing totalling €21m incl co-investor Crédit Mutuel Innovation |
2022-07-07 |
Ganymed Robotics–Eurazeo: investment, 202207 financing round Series B first closing totalling €21m incl co-investor Kurma Partners |
2022-07-07 |
Ganymed Robotics–OTHER: investment, 202207 financing round Series B first closing totalling €21m incl internationallly renowned surgeons |
2022-07-07 |
Ganymed Robotics–SEVERAL: investment, 202207 financing round Series B first closing €21m led by Cathay Health |
2022-07-07 |
Aurobac Therapeutics–Boehringer: investment, 202207 launch of €40m joint venture Aurobac incl €30m from lead investor Boehringer Ingelheim |
2022-07-06 |
Boehringer–Evotec: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor Evotec |
2022-07-06 |
Boehringer–Mérieux: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor bioMérieux |
2022-07-06 |
Epizyme–Ipsen: investment, 202206– cash tender offer $247m + 1CVR/share ANNOUNCED |
2022-06-27 |
Micropep Technologies–CEA Industrie: investment, 202206 financing round Series A1 totalling €8.75m incl existing + co-investor Supernova Invest |
2022-06-27 |
Micropep Technologies–Fall Line Capital: investment, 202206 financing round Series A1 totalling €8.75m incl new + lead investor Fall Line Capital |
2022-06-27 |
Micropep Technologies–FMC: investment, 202206 financing round Series A1 totalling €8.75m incl existing + co-investor FMC Ventures |
2022-06-27 |
Micropep Technologies–Irdi Soridec: investment, 202206 financing round Series A1 totalling €8.75m incl existing + co-investor Irdi/Soridec |
2022-06-27 |
Micropep Technologies–SEVERAL: investment, 202206 financing round Series A1 €8.75m led by new investor Fall Line Capital |
2022-06-27 |
Micropep Technologies–Sofinnova: investment, 202206 financing round Series A1 totalling €8.75m incl existing + co-investor Sofinnova Partners |
2022-06-27 |
Kranus Health–Karista: investment, 202206 financing round Series A totalling >$6.5m incl lead investor Karista |
2022-06-20 |
Kranus Health–SEVERAL: investment, 202206 financing round Series A >$6.5m led by Karista |
2022-06-20 |
Valneva–Pfizer: investment, 202206 equity investment via capital increase €90.5m (representing 8.1% if capital) at €9.49/share |
2022-06-20 |
ImCheck Therapeutics–Agent Capital: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Agent Capital |
2022-06-13 |
ImCheck Therapeutics–Alexandria Real Estate: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Alexandria VI |
2022-06-13 |
ImCheck Therapeutics–Andera Partners: investment, 202206 financing round Series C totalling €80m incl new + co-lead investor Andera Partners |
2022-06-13 |
ImCheck Therapeutics–Bellevue: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Pureos Bioventures |
2022-06-13 |
ImCheck Therapeutics–Boehringer: investment, 202206 financing round Series C totalling €80m incl existing + co-investor BIVF |
2022-06-13 |
ImCheck Therapeutics–Earlybird: investment, 202206 financing round Series C totalling €80m incl new + co-lead investor Earlybird |
2022-06-13 |
ImCheck Therapeutics–EQT: investment, 202206 financing round Series C totalling €80m incl existing + co-investor EQT Life Sciences |
2022-06-13 |
ImCheck Therapeutics–Eurazeo: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Eurazeo |
2022-06-13 |
ImCheck Therapeutics–Eurazeo: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Kurma Partners GO Fund |
2022-06-13 |
ImCheck Therapeutics–France (govt): investment, 202206 financing round Series C totalling €80m incl existing + co-investor Bpifrance Innobio 2 + LV |
2022-06-13 |
ImCheck Therapeutics–Gimv: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Gimv |
2022-06-13 |
ImCheck Therapeutics–Invus Group: investment, 202206 financing round Series C totalling €80m incl new + co-investor Invus |
2022-06-13 |
ImCheck Therapeutics–Leukemia & Lymphoma Society: investment, 202206 financing round Series C totalling €80m incl new + co-investor LLS TAP |
2022-06-13 |
ImCheck Therapeutics–Pfizer: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Pfizer Ventures |
2022-06-13 |
ImCheck Therapeutics–SEVERAL: investment, 202206 financing round Series C €80m co-led by new investors Earlybird + Andera Partners |
2022-06-13 |
ImCheck Therapeutics–Wellington Partners: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Wellington Partners |
2022-06-13 |
Ariceum Therapeutics–Optimum Strategic Communications: public relations, 202206 service existent by Optimum |
2022-06-08 |
Ariceum Therapeutics–SEVERAL: investment, 202206 financing round Series A €25m co-led by HealthCap + EQT Life Sciences |
2022-06-08 |
Weezion–Mérieux: in-vitro diagnostics, 202206– collab technical assistance from bioMérieux to develop MS-based sepsis IVD |
2022-06-01 |
Weezion–Mérieux: investment, 202206 investment €2m from bioMérieux for a 4.26% share accompanied by technical assistance |
2022-06-01 |
Minoryx–SEVERAL: credit, 202205 complementary bank debt to Series C financing round (both tog totalling €51m) |
2022-05-31 |
Minoryx–SEVERAL: investment, 202205 financing round Series C (incl complementary bank totalling €51m) led by Columbus VP + Caixa Capital Risc |
2022-05-31 |
Repertoire Genesis–Eurofins: investment, 202205 acquisition of majority stake by Eurofins Scientific |
2022-05-31 |
Advent Life Sciences–Scius Communications: public relations, 202205 supply service existent by Scius Communications |
2022-05-26 |
Apollo Global Management–Sofinnova: life science financing, 202205– strategic partnership incl investm in Sofinnova Partners + up to $1b capital |
2022-05-16 |
Sofinnova–Apollo Global Management: investment, 202205– acquisition of minority equity interest in Sofinnova Partners as part of strategic partnership |
2022-05-16 |
Sofinnova–Apollo Global Management: investment, 202205– commitment of up to $1b managed capital to Sofinnova Partners investment funds by Apollo |
2022-05-16 |
NanoPhoria–Sofinnova: investment, 202205 seed financing €3.5m from Sofinnova Telethon Fund |
2022-05-12 |
Domain Therapeutics–BPCE: investment, 202205 financing round Series A totalling €39m incl existing + co-investor Seventure Partners |
2022-05-10 |
Domain Therapeutics–Canada (govt): investment, 202205 financing round Series A totalling €39m incl co-investor adMare BioInnovations |
2022-05-10 |
Domain Therapeutics–CTI Life Sciences: investment, 202205 financing round Series A totalling €39m incl co-lead investor CTI Life Sciences |
2022-05-10 |
Domain Therapeutics–Helsinn: investment, 202205 financing round Series A totalling €39m incl co-lead investor 3B Future Health Fund |
2022-05-10 |
Domain Therapeutics–Omnes Capital: investment, 202205 financing round Series A totalling €39m incl co-investor Omnes |
2022-05-10 |
Domain Therapeutics–Panacea Venture: investment, 202205 financing round Series A totalling €39m incl co-lead investor Panacea Venture |
2022-05-10 |
Domain Therapeutics–Schroders: investment, 202205 financing round Series A totalling €39m incl co-investor Schroders Capital |
2022-05-10 |
Domain Therapeutics–SEVERAL: investment, 202205 financing round Series A €39m co-led by Panacea Venture + CTI Life Sciences + 3B Future Health Fund |
2022-05-10 |
Domain Therapeutics–Theodorus: investment, 202205 financing round Series A totalling €39m incl co-investor Theodorus |
2022-05-10 |
Domain Therapeutics–Turenne: investment, 202205 financing round Series A totalling €39m incl co-investor Turenne Capital/Sham Innovation Santé |
2022-05-10 |
Domain Therapeutics–Viva Biotech: investment, 202205 financing round Series A totalling €39m incl co-investor Viva BioInnovator |
2022-05-10 |
Tubulis–Andera Partners: investment, 202205 financing round Series B totalling €60m incl new + lead investor Andera Partners |
2022-05-03 |
Tubulis–BPCE: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Seventure Partners |
2022-05-03 |
Tubulis–SEVERAL: investment, 202205 financing round Series B €60m led by new investor Andera Partners |
2022-05-03 |
OMass–SEVERAL: investment, 202204 financing round Series B £75.5m led by new investors GV + Northpond Ventures + Sanofi Ventures |
2022-04-28 |
Peak Proteins–Sygnature Discovery: investment, 202204 acquisition €na of Peak Proteins by Sygnature Discovery |
2022-04-26 |
CDR-Life–Jeito Capital: investment, 202204 financing round Series A totalling $76m incl co-lead investor Jeito Capital |
2022-04-13 |
CDR-Life–SEVERAL: investment, 202204 financing round Series A $76m co-led by Jeito Capital + RA Capital |
2022-04-13 |
Ribonexus–France (govt): credit, 202204– repayable advance €1.4m via Future Investments Program from Bpifrance |
2022-04-12 |
Ribonexus–France (govt): grant, 202204– grant €600k via Future Investments Program from Bpifrance |
2022-04-12 |
Carmat–SEVERAL: investment, 202204 global offering €40.5m via issuance of 4.05m new shares |
2022-04-11 |
LimFlow–Balestier: investment, 202204 financing round Series D totalling €36m incl existing investor Balestier family fund |
2022-04-06 |
LimFlow–France (govt): investment, 202204 financing round Series D totalling €36m incl existing investor Bpifrance |
2022-04-06 |
LimFlow–Longitude Capital: investment, 202204 financing round Series D totalling €36m incl new investor Longitude Capital |
2022-04-06 |
LimFlow–OTHER: investment, 202204 financing round Series D totalling €36m incl new undisclosed strategic investor |
2022-04-06 |
LimFlow–SEVERAL: investment, 202204 financing round Series D €36m with new + existing investors |
2022-04-06 |
LimFlow–Sofinnova: investment, 202204 financing round Series D totalling €36m incl existing investor Sofinnova Partners |
2022-04-06 |
LimFlow–Soleus Capital: investment, 202204 financing round Series D totalling €36m incl new investor Soleus Capital |
2022-04-06 |
Bio-Medical Science–DNA Script: DNA synthesis system, 202204– distribution of Syntax EDS System by Bio-Medical Science in Korea |
2022-04-05 |
Cold Spring Biotech–DNA Script: DNA synthesis system, 202204– distribution of Syntax EDS System by Cold Spring in China, Taiwan + Hong Kong |
2022-04-05 |
Premas Life Sciences–DNA Script: DNA synthesis system, 202204– distribution of Syntax EDS System by Premas Life Sciences in India |
2022-04-05 |
Research Instruments (SG)–DNA Script: DNA synthesis system, 202204– distribution of Syntax EDS System by Research Instruments in Singapore |
2022-04-05 |
CardioRenal–SEVERAL: investment, 202204 seed financing round €3.3m from businses angels + management |
2022-04-04 |
Axa–Canary Wharf Group: real estate, 202203– collab joint venture of Kadans Science Partner + CWG to built wet lab buliding in Canary Wharf London |
2022-03-30 |
Core Biogenesis–Blue Horizon Ventures: investment, 202203 financing round Series A totalling €10m incl new + co-lead investor Blue Horizon Ventures |
2022-03-29 |
Core Biogenesis–Entrepreneur First: investment, 202203 financing round Series A totalling €10m incl existing + co-investor Entrepreur First |
2022-03-29 |
Core Biogenesis–OTHER: investment, 202203 financing round Series A totalling €10m incl business angels as investors |
2022-03-29 |
Core Biogenesis–SEVERAL: investment, 202203 financing round Series A €10m led by XAnge + Blue Horizon Ventures |
2022-03-29 |
Core Biogenesis–Siparex: investment, 202203 financing round Series A totalling €10m incl existing + co-lead investor XAnge |
2022-03-29 |
Sanofi–IGM Biosciences: IgM antibody agonists, 202203– collab RnD + commerc ww excl $150m upfront + >$6b milestones for cancer + inflammation |
2022-03-29 |